Literature DB >> 27117583

Evaluation of role of telmisartan in combination with 5-fluorouracil in gastric cancer cachexia.

Shreesha Sukumaran1, Hetal J Patel2, Bhoomika M Patel3.   

Abstract

BACKGROUND: The objective of the present study was to evaluate the effect of combination of telmisartan with 5-flourouracil (5-FU) in gastric cancer cachexia induced by administering N-methyl-N'-methyl-N-nitrosoguanidine (MNNG).
METHOD: MNND was administered once daily by oral gavage for two weeks, and saturated NaCl (1ml per rat) was then given once every 3days for 4weeks. 5-FU (75mg/kg, i.v.) was administered once three weeks from 7th to 22nd week. From 7th to 22nd week, telmisartan (5mg/kg, p.o.) was also administered along with 5-FU. RESULT: MNNG produced significant decrease in food intake, body weight, caused hyperglycemia, dyslipidemia, hypertension worsened hemodyanamics, increased cachexia markers and increased tumor markers like lactate dehydrogenase and γ-glutamyltransferase. MNNG also produced oxidative stress in the stomach tissue. Treatment with combination of telmisartan with 5-FU produced significant increase in food intake and body weight, controlled hyperglycemia and dyslipidemia, preserved hemodynamic function, and decreased the cachexia markers while 5-FU alone did not produce any such effects. Further, the combination of telmisartan with 5-FU significantly reduced tumor marker levels, oxidative stress and also significantly decreased the cell proliferation, apoptosis, hyperkeratosis, keratohyaline granules and invasive carcinoma of forestomach and reduced muscle atrophy in tibilias anterior skeletal muscle.
CONCLUSION: Our data suggests that combination of telmisartan with 5-FU treatment is beneficial in controlling cancer cachexia. Telmisartan can be used as an add-on therapy with 5-FU or other traditional chemotherapeutic agents.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dyslipidemia; Gastric cancer cachexia; Hyperglycemia; IL-6; Muscle atrophy

Mesh:

Substances:

Year:  2016        PMID: 27117583     DOI: 10.1016/j.lfs.2016.04.029

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  5 in total

Review 1.  Cardiac Complications: The Understudied Aspect of Cancer Cachexia.

Authors:  Vivek Bora; Bhoomika Patel
Journal:  Cardiovasc Toxicol       Date:  2022-02-16       Impact factor: 3.231

2.  Telmisartan inhibits NSCLC A549 cell proliferation and migration by regulating the PI3K/AKT signaling pathway.

Authors:  Suolin Zhang; Yayan Wang
Journal:  Oncol Lett       Date:  2018-02-08       Impact factor: 2.967

Review 3.  Altered glucose metabolism and insulin resistance in cancer-induced cachexia: a sweet poison.

Authors:  Tamhida Masi; Bhoomika M Patel
Journal:  Pharmacol Rep       Date:  2020-11-03       Impact factor: 3.024

4.  Telmisartan Induces Osteosarcoma Cells Growth Inhibition and Apoptosis Via Suppressing mTOR Pathway.

Authors:  Chao Wang; Wen-Bo Wang
Journal:  Open Life Sci       Date:  2018-07-05       Impact factor: 0.938

5.  Angiotensin receptor blocker telmisartan inhibits cell proliferation and tumor growth of cholangiocarcinoma through cell cycle arrest.

Authors:  Eri Samukawa; Shintaro Fujihara; Kyoko Oura; Hisakazu Iwama; Yoshimi Yamana; Tomoko Tadokoro; Taiga Chiyo; Kiyoyuki Kobayashi; Asahiro Morishita; Mai Nakahara; Hideki Kobara; Hirohito Mori; Keiichi Okano; Yasuyuki Suzuki; Takashi Himoto; Tsutomu Masaki
Journal:  Int J Oncol       Date:  2017-10-23       Impact factor: 5.650

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.